Frovatriptan - NDSRI's
References
FAQ's
References
- Kitteringham, John; Porter, Roderick A.; Shipton, Mark R.; Vimal, Mythily; Young, Rodney C.; Borrett, Gary T., Process for preparing an enantiomer of a carbazole derivative, Smithkline Beecham P.L.C., United Kingdom, US5618948A, April 8, 1997
- Khan, Muzaffar; Viswanathan, Balaji; Rao, D. Sreenivas; Reddy, Rajasekhar, Chiral separation of Frovatriptan isomers by HPLC using amylose based chiral stationary phase, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences Volume: 846, Issue: 1-2, Pages: 119-123, 2007
Frequently Asked Questions
Are Frovatriptan impurities monitored during its shelf life?
The impurities in Frovatriptan are monitored during its shelf life to ensure the stability and quality of the medication. Stability testing helps assess their presence and levels over the designated shelf-life period. It ensures that impurity levels remain within acceptable limits and do not increase over time.
How are Frovatriptan impurities reported and managed by regulatory authorities?
Regulatory authorities require manufacturers to provide detailed information about impurities in Frovatriptan as part of the drug approval process. It includes the identification, characterization, and control strategies for impurities. Regulatory agencies review and assess the impurity data to ensure compliance with established guidelines and to verify the safety and quality of Frovatriptan.
Which solvent helps in analyzing Frovatriptan impurities?
Water is the solvent used when analyzing many impurities in Frovatriptan.
How should Frovatriptan impurities be stored in terms of temperature?
The recommendation is to store Frovatriptan impurities at a controlled room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.